Therapeutic Expansion of JAK Inhibitors in Chinese Dermatological Practice: Beyond Atopic Dermatitis to Novel Autoimmune Frontiers

    August 2026 in “ Frontiers in Medicine ”
    Xinyan Lyu, Yixi Wang, Jingyi Yang … Na Du
    Studysummary This review discusses the potential applications of JAK inhibitors in various dermatological conditions beyond atopic dermatitis, emphasizing gaps in evidence and therapeutic opportunities in the context of Chinese clinical practice, but reports no new clinical results.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on frontiersin.org →
    Discuss this study in the Community →

    Research cited in this study 10

    1. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program American journal of clinical dermatology · 2024
    2. Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management Clinical Reviews in Allergy & Immunology · 2021
    3. Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata Drug design, development and therapy · 2018
    4. Alopecia Areata: A Review of Disease Pathogenesis British journal of dermatology/British journal of dermatology, Supplement · 2018
    5. Topical 2% Tofacitinib for Children with Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Journal of the American Academy of Dermatology · 2018
    6. A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata Journal of cutaneous medicine and surgery · 2017
    7. Topical Janus Kinase Inhibitors for the Treatment of Pediatric Alopecia Areata Journal of the American Academy of Dermatology · 2017
    8. Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata JCI insight · 2016
    9. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016
    10. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014